Cross-agency comparison: 🇬🇧 MHRA leads with 31 documents in 90 days

FDA vs EMA vs MHRA vs Health Canada — who's most active?

This cross-agency pattern suggests the UK MHRA has been the most active source of recent regulatory output, with Health Canada also relatively busy, while FDA and EMA appear similarly active but slightly less prolific over the same period. Sponsors should consider that this may indicate the fastest-moving policy and procedural expectations are currently emerging outside the core US/EU centers, which could favor earlier monitoring of UK and Canadian signals when shaping a global submission strategy. For resource planning, this could suggest building more flexibility into dossier maintenance, labeling, and post-submission response capacity, because multi-market filing programs may need to absorb staggered updates rather than relying on a single dominant regulatory cadence.